Background
Symptomatic patients with significant left ventricular systolic dysfunction (LVSD) require a tailored treatment approach. Both functional mitral regurgitation (FMR) and left bundle branch block (LBBB) can develop, contributing to clinical deterioration, and worse prognosis despite optimal medical therapy (OMT). 
Learning points
• Functional mitral regurgitation and left bundle branch block are frequently present in patients with symptomatic severe left ventricular systolic dysfunction despite guideline-based optimal medical therapy, and pathways of care should be responsive to changing clinical circumstances.
• Cardiac resynchronization therapy (CRT) in accordance with current heart failure/CRT guidelines remains technically achievable in the presence of a Carillon V R Mitral Contour System V R annuloplasty device and can be accomplished as a day-case under local anaesthetic using standard techniques and equipment.
Introduction
Functional mitral regurgitation (FMR) is a common finding in cardiomyopathy patients with both ischaemic and non-ischaemic left ventricular systolic dysfunction (LVSD), 1 being associated with worse symptoms and higher morbidity and mortality. The mitral valve is usually structurally normal, but ventricular (or atrial) dilatation or associated regional wall motion abnormalities can result in lateral displacement and mitral leaflet mal-coaptation leading to secondary (functional) mitral regurgitation (MR). 
Investigations
Echocardiogram (February 2019, Figure 1B) showing severe LVSD and mild MR (previously moderate-severe on transthoracic and transoesophageal echocardiograms in July 2018, prior to Carillon Figure 1A ; Supplementary material online, Video S1), known moderate diffuse coronary artery disease on coronary angiogram (2017), sinus rhythm with new LBBB on electrocardiogram (QRS duration 142 ms in January 2019, previously 110 ms in 2018).
Differential diagnosis
His current deterioration in symptoms was deemed to be the result of developing LBBB with severe LVSD, despite initial symptomatic improvement following Carillon V R device implant and optimal medical therapy (OMT). 
Follow-up
The patient was discharged the same day uneventfully and was reviewed one week later in the pacing clinic for pacemaker parameter interrogation and incision area evaluation, with no issues identified. He has also reported a reduction in shortness of breath and resolution of orthopnoea symptoms on telephone consultation review with the HF specialist nursing team at 2 weeks; and was deemed to have a symptom burden of NYHA Class II when reviewed in the Heart Failure Clinic in June 2019 (see Timeline).
Discussion
Guideline-based OMT can improve LV systolic function, reduce MR severity, and increase exercise capacity. 1 In those with conduction delay, CRT is a well-established recommended treatment, improving FMR, symptoms, and prognosis. 3, 5 For patients without a traditional CRT indication, surgical correction of FMR is not associated with improved outcomes. 6 This has led to an increasing drive to find percutaneous techniques to reduce the FMR, with low peri-procedural risk. 7 Recent trials have heightened anticipation that such percutaneous approaches might improve both symptoms and outcomes. 2, 8 Percutaneous mitral annuloplasty using the Carillon V R device is a fully transvenous approach utilizing the anatomical proximity of the CS to the mitral ring, that can lead to clinically relevant reductions in FMR. 3 The device consists of distal and proximal anchors linked by a flexible nitinol bridge which, when deployed within the CS, can reduce FMR by externally restricting the mitral annulus diameter.
3,9
However, HFrEF is a progressive disease process, one feature of which is the development of new conduction abnormalities. 10 Observational studies have described an incidence of new-onset LBBB of up to 10% at 1 year even in ostensibly stable patients.
11
New intraventricular conduction delay and QRS prolongation are associated with increased symptoms, worsening LV function, accelerated remodelling, increased risk of ventricular arrhythmias and sudden death and are an independent risk factor for all-cause mortality. 12, 13 The presence of LBBB also predicts lower rates of reverse remodelling, 14 and intraventricular conduction delay, especially LBBB is associated with worse FMR by lengthening LV isovolumetric contraction and relaxation. There is no evidence from observational studies or trials suggesting that device-based treatments for FMR are associated with the development of intraventricular delay or conduction abnormalities. Thus, our interpretation was that the development of new LBBB reported, in this case, is in keeping with the observed natural history of the underlying disease process.
There have been very few cases of CRT implantation in the presence of a Carillon V R Mitral Contour System V R annuloplasty device. [15] [16] [17] [18] The first reported case series by Hoppe et al. demonstrated the feasibility of successful CRT after percutaneous mitral annuloplasty, while in the other reported cases, the patients had pre-existing LBBB and ongoing symptoms following Carillon V R device implant.
Several concerns arise when contemplating LV lead implantation through the Carillon V R device, particularly around CS cannulation due to altered geometry and increased tortuosity or angulation. Other potential questions around lead positioning and stability and the risks of CS dissection have been raised. 6 In practice, as can be seen from our image (Figure 1) , the Carillon V R device provides easy visualization of the CS anatomy and orientation, facilitating direct access. Furthermore, tension from the device also reduces any tortuosity or angulation at the ostia of tributaries, potentially increasing the ease of LV lead placement. The conceivable risk of dislodgement of the Carillon system can be disregarded since intravascular-ultrasound data have demonstrated complete endothelialization of the anchors of the Carillon device within 6 months of implant. 10 Placing a Carillon V R Mitral Contour System V R over an existing transvenous CRT lead is currently not recommended, although a series of animal experiments demonstrated the feasibility and stability of the Carillon V R Mitral Contour System V R implanted in the presence of LV leads, and also that these leads could be extracted without migration of the Carillon V R device and without acute or long-term vascular complications. 19 
Conclusion
This case highlights the complexity of caring for a patient with symptomatic HFrEF, and that pathways of care should be responsive to changing clinical circumstances. We have demonstrated that a transvenous quadripolar LV lead can be safely implanted in the presence of a Carillon 
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